Literature DB >> 26677253

Synergy of β-Lactams with Vancomycin against Methicillin-Resistant Staphylococcus aureus: Correlation of Disk Diffusion and Checkerboard Methods.

Cheng Len Sy1, Tsi-Shu Huang2, Chii Shiang Chen2, Yao-Shen Chen3, Hung-Chin Tsai3, Shue-Renn Wann1, Kuan-Sheng Wu3, Jui-Kuang Chen1, Susan Shin-Jung Lee4, Yung-Ching Liu5.   

Abstract

Modified disk diffusion (MDD) and checkerboard tests were employed to assess the synergy of combinations of vancomycin and β-lactam antibiotics for 59 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and Mu50 (ATCC 700699). Bacterial inocula equivalent to 0.5 and 2.0 McFarland standard were inoculated on agar plates containing 0, 0.5, 1, and 2 μg/ml of vancomycin. Oxacillin-, cefazolin-, and cefoxitin-impregnated disks were applied to the surface, and the zones of inhibition were measured at 24 h. The CLSI-recommended checkerboard method was used as a reference to detect synergy. The MICs for vancomycin were determined using the Etest method, broth microdilution, and the Vitek 2 automated system. Synergy was observed with the checkerboard method in 51% to 60% of the isolates when vancomycin was combined with any β-lactam. The fractional inhibitory concentration indices were significantly lower in MRSA isolates with higher vancomycin MIC combinations (P < 0.05). The overall agreement between the MDD and checkerboard methods to detect synergy in MRSA isolates with bacterial inocula equivalent to McFarland standard 0.5 were 33.0% and 62.5% for oxacillin, 45.1% and 52.4% for cefazolin, and 43.1% and 52.4% for cefoxitin when combined with 0.5 and 2 μg/ml of vancomycin, respectively. Based on our study, the simple MDD method is not recommended as a replacement for the checkerboard method to detect synergy. However, it may serve as an initial screening method for the detection of potential synergy when it is not feasible to perform other labor-intensive synergy tests.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26677253      PMCID: PMC4767953          DOI: 10.1128/JCM.01779-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  The effects of vancomycin and beta-lactam antibiotics on vancomycin-resistant Staphylococcus aureus.

Authors:  I Haraga; S Nomura; A Nagayama
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories.

Authors:  E Matuschek; D F J Brown; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2013-10-17       Impact factor: 8.067

3.  Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yasemin Oz
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

4.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Estimating the precision of disc diffusion antibiotic susceptibility data published by the European committee on antimicrobial susceptibility testing.

Authors:  Peter Smith; Göran Kronvall
Journal:  APMIS       Date:  2014-04-14       Impact factor: 3.205

Review 6.  Synergism and antagonism.

Authors:  G M Eliopoulos
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

7.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

9.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

10.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  8 in total

1.  The synergistic effect of hydroalcoholic extracts of Origanum vulgare, Hypericum perforatum and their active components carvacrol and hypericin against Staphylococcus aureus.

Authors:  Mahmoud Bahmani; Morovat Taherikalani; Mojtaba Khaksarian; Mahmoud Rafieian-Kopaei; Behnam Ashrafi; Mohammadreza Nazer; Setareh Soroush; Naser Abbasi; Marzieh Rashidipour
Journal:  Future Sci OA       Date:  2019-01-31

2.  Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?

Authors:  Yamuna Devi Bakthavatchalam; Ravikar Ralph; Balaji Veeraraghavan; Priyanka Babu; Elakkiya Munusamy
Journal:  Infect Dis Ther       Date:  2018-11-21

3.  Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation.

Authors:  Saskia Zimmermann; Mareike Klinger-Strobel; Jürgen A Bohnert; Sindy Wendler; Jürgen Rödel; Mathias W Pletz; Bettina Löffler; Lorena Tuchscherr
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

4.  Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia.

Authors:  Karen Tan; Emi Minejima; Mimi Lou; Wendy J Mack; Paul Nieberg; Annie Wong-Beringer
Journal:  BMC Infect Dis       Date:  2021-04-05       Impact factor: 3.090

5.  Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.

Authors:  Chunmei Xie; Christian Tiede; Xuanyi Zhang; Congrong Wang; Zhixiong Li; Xiao Xu; Michael J McPherson; Darren C Tomlinson; Weiwen Xu
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

6.  Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria.

Authors:  Juliana Januario Gaudereto; Lauro Vieira Perdigão Neto; Gleice Cristina Leite; Evelyn Patricia Sanchez Espinoza; Roberta Cristina Ruedas Martins; Gladys Villas Boa Prado; Flavia Rossi; Thais Guimarães; Anna Sara Levin; Silvia Figueiredo Costa
Journal:  BMC Microbiol       Date:  2020-04-16       Impact factor: 3.605

7.  Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Authors:  Arpasiri Srisrattakarn; Chonthicha Chaiyapoke; Sirikarn Booncharoen; Sujintana Wongthong; Aroonwadee Chanawong; Patcharaporn Tippayawat; Ratree Tavichakorntrakool; Aroonlug Lulitanond
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

8.  Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin.

Authors:  Olajumoke A Olateju; Chinedum P Babalola; Olujide O Olubiyi; Olayinka A Kotila; David A Kwasi; Anderson O Oaikhena; Iruka N Okeke
Journal:  Front Microbiol       Date:  2021-06-02       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.